- Home
- PETS vs ACRV Comparison
PETS vs ACRV Comparison
Compare PETS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ACRV
- Stock Information
- Founded
- PETS 1996
- ACRV 2018
- Country
- PETS United States
- ACRV United States
- Employees
- PETS N/A
- ACRV N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- PETS Consumer Staples
- ACRV Health Care
- Exchange
- PETS Nasdaq
- ACRV Nasdaq
- Market Cap
- PETS 57.8M
- ACRV 47.8M
- IPO Year
- PETS N/A
- ACRV 2022
- Fundamental
- Price
- PETS $1.99
- ACRV $2.26
- Analyst Decision
- PETS Sell
- ACRV Buy
- Analyst Count
- PETS 1
- ACRV 5
- Target Price
- PETS $3.20
- ACRV $14.67
- AVG Volume (30 Days)
- PETS 176.5K
- ACRV 1.2M
- Earning Date
- PETS 11-03-2025
- ACRV 11-13-2025
- Dividend Yield
- PETS N/A
- ACRV N/A
- EPS Growth
- PETS N/A
- ACRV N/A
- EPS
- PETS N/A
- ACRV N/A
- Revenue
- PETS $226,972,000.00
- ACRV N/A
- Revenue This Year
- PETS N/A
- ACRV N/A
- Revenue Next Year
- PETS $2.98
- ACRV $805.34
- P/E Ratio
- PETS N/A
- ACRV N/A
- Revenue Growth
- PETS N/A
- ACRV N/A
- 52 Week Low
- PETS $1.93
- ACRV $1.05
- 52 Week High
- PETS $6.85
- ACRV $8.35
- Technical
- Relative Strength Index (RSI)
- PETS 34.39
- ACRV 58.68
- Support Level
- PETS $1.93
- ACRV $1.78
- Resistance Level
- PETS $2.92
- ACRV $2.35
- Average True Range (ATR)
- PETS 0.16
- ACRV 0.20
- MACD
- PETS -0.04
- ACRV 0.01
- Stochastic Oscillator
- PETS 6.57
- ACRV 69.83
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.